| Name | Title | Contact Details |
|---|---|---|
Solomon Wang |
Director, IT | Profile |
Rheonix, Inc. is committed to improving standards of care by making molecular diagnostics available to more people, in more places, more often. As scientific knowledge evolves, so does the need for new diagnostic technology to simplify processes and enhance innovation. Rheonix, through experienced leadership and creative vision, has developed the Encompass platform, a highly customizable technology with unmatched versatility and affordability. The platform performs fully automated, complex molecular assays in an easy to use and economical format on the Rheonix CARD® cartridge. With both the Rheonix CARD and Encompass family of products, Rheonix is well-positioned to penetrate key molecular diagnostic market sectors, from reference labs through point-of-care and everywhere in-between.
At Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the gut informs our brains about our well-being, metabolism, and nutritional state. The gut-brain axis—the communication highway between our gut and our brain—offers an unprecedented opportunity to access and influence brain centers involved in fundamental human processes. An understanding of the biology mediated by the gut and gut-brain circuits will change the way we think about food, nutrition, and human physiology. Founded and headquartered in New York City, we are developing an industry-leading platform to harness the gut-brain axis. Our cross-disciplinary biotechnology team will integrate cutting-edge technologies in sequencing, bioinformatics, neural imaging, cellular and molecular biology, and human genetics to provide an understanding of gut-brain biology that will lead to transformational therapeutics and consumer products to improve human health and nutrition.
Precision Medicine. Precision Therapies.Hummingbird Bioscience is leading a bold new way of engineering precision biotherapeutics that can define the future of precision medicine. We focus on important biologically validated targets in cancer and autoi...
We work at the intersection of biology, engineering, and design, developing technologies that emulate human biology. Our products are enabling a new era of precision medicine and the development of applications for personalized health. Our Human Emulation System, which uses Organs-on-Chips technology, is being used by industry, government, and academia to understand how different diseases, medicines, chemicals and foods affect human health. The system offers researchers a new standard for predicting human response — with greater precision and control than today`s cell culture or animal-based experimental methods. We are also leading a bold, new precision medicine initiative with our clinical partners. Named "Patient-on-a-Chip," the program is developing personalized chips with patients` own cells. This initiative will help transform the way each of us understands our own bodies and manages our own health. Research conducted using our Organ-Chips has been published in high-impact scientific journals, including Science. In addition, Organ-Chips have been acquired by the Museum of Modern Art (MoMA) in New York for their permanent collection, and have also been awarded Product Design of the Year 2015 by London`s Design Museum. Our founding team pioneered the original Organs-on-Chips technology during their residency within the Wyss Institute for Biologically Inspired Engineering at Harvard University.
Founded in 2006, InGeneron is a privately held company, developing its own products for multiple markets and expanding its reach through licensing agreements. The company was formed to innovate cell-based technologies for healthcare and life science research. Headquartered in Houston, Texas,